Rainbow BioSciences, the biotech division of Rainbow Coral Corp. (OTCBB: RBCC) announced today that it has initiated talks with a drug development company pursuing a promising new therapy for Parkinson’s disease.

The market for Parkinson's disease drugs could reach a value of $3.75 billion by 2015, according to a 2011 report by business info provider Visiongain. New drugs and other products could significantly boost the Parkinson's treatment market and help advance the timeline for a cure for this debilitating disease.

RBCC is always searching for new partnerships, joint ventures, and possible acquisitions that could increase the company’s revenues and exposure in the biotech industry. The company is working on agreements with rising stars in need of assistance in funding, marketing and distributing their projects—RBCC’s specialty.

The company is exploring a possible deal with the drug therapy company as well as others as it pursues promising new opportunities for rapid growth.

For more information on Rainbow BioSciences, Rainbow Coral’s biotech division, please visit www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).

Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.